OstomyCure appoints Geir Christian Melen as Chief Executive Officer
OstomyCure AS, a company focused on developing novel products for stoma patients, announces that it has appointed Geir Christian Melen as its Chief Executive Officer (CEO). At OstomyCure, Mr. Melen will be responsible for the development and commercialization of TIES®, a proprietary implant system focused on dramatically improving the lives of stoma patients. "I look forward to joining OstomyCure at a time of great potential", Geir Christian Melen commented. - OstomyCure has embarked on the clinical development phase for TIES® and I believe this new medical device can be brought successfully to market on an international basis.
"I am delighted to welcome Geir Christian ", said Johan Gjesdahl, OstomyCure´s Chairman. "He is an entrepreneurial business leader who has delivered remarkable results in each of his previous positions. With OstomyCure’s groundbreaking technology and large addressable market, I am confident he will be equally successful in establishing OstomyCure as a leading company in the field of innovative products for stoma patients”.
Geir Christian Melen has significant senior management experience from companies focused on the development and commercialization of novel health care products (Clavis Pharma ASA, Algeta, Photocure). He comes to the position from Clavis Pharma ASA, a cancer drug development company, where he was CEO since April 2008.
